Wedbush Starts Hemab Therapeutics Holdings (COAG) at Outperform

Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Outperform rating and a price target of $42.00.

The analyst comments "We view Hemab Therapeutics (NASDAQ: COAG) as a high conviction opportunity within rare coagulation disorders. COAG is developing subcutaneous prophylactic antibody therapies for inherited bleeding disorders where current treatment is dominated by burdensome IV factor replacement or lack approved prophylactic options. The lead asset, sutacimig (HMB-001), is a bispecific antibody that restores clotting capability by recruiting endogenous Factor VII/VIIa to activated platelets via TLT-1 binding, restoring localized thrombin generation in Glanzmann thrombasthenia (GT) and driving Factor VII accumulation in severe Factor VII deficiency (FVIID). Ph 1/2 GT data support advancement into a single-arm pivotal Ph 3 trial expected to initiate in 2H26. Sutacimig is also in a Ph 2 FVIID study with proof-of-concept data expected in late 2026 or early 2027. COAG’s second program, HMB-002, is a monovalent antibody that stabilizes endogenous VWF and Factor VIII as a subcutaneous prophylactic for Von Willebrand disease (VWD), the most common inherited bleeding disorder. With multiple proof-of-concept catalysts over 6–12 months, minimal direct competition from similarly targeted mechanisms, and cash runway into 2029, we view COAG as well positioned to build a differentiated prophylactic coagulation franchise."

For an analyst ratings summary and ratings history on Hemab Therapeutics Holdings click here. For more ratings news on Hemab Therapeutics Holdings click here.

Shares of Hemab Therapeutics Holdings closed at $25.89 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• Barclays Downgrades PolyPeptide Group AG (PPGN:SW) to Equalweight
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold